Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 34

1.

Thalidomide in the management of multiple myeloma.

Barlogie B, Zangari M, Spencer T, Fassas A, Anaissie E, Badros A, Cromer J, Tricot G.

Semin Hematol. 2001 Jul;38(3):250-9. Review.

PMID:
11486313
2.

Thalidomide in the management of multiple myeloma.

Barlogie B, Tricot G, Anaissie E.

Semin Oncol. 2001 Dec;28(6):577-82. Review.

PMID:
11740812
3.

Management of the relapsed/refractory myeloma patient: strategies incorporating lenalidomide.

Richardson P.

Semin Hematol. 2005 Oct;42(4 Suppl 4):S9-15. Review.

PMID:
16344100
4.

Thalidomide treatment in multiple myeloma.

Strasser K, Ludwig H.

Blood Rev. 2002 Dec;16(4):207-15. Review.

PMID:
12350364
5.

[New treatment strategy of multiple myeloma for cure].

Murakami H, Handa H.

Gan To Kagaku Ryoho. 2006 Apr;33(4):417-23. Review. Japanese.

PMID:
16612147
6.

Thalidomide in multiple myeloma.

Moehler TM, Hillengass J, Glasmacher A, Goldschmidt H.

Curr Pharm Biotechnol. 2006 Dec;7(6):431-40. Review.

PMID:
17168659
7.

Lenalidomide in multiple myeloma.

Richardson PG, Mitsiades C, Hideshima T, Anderson KC.

Expert Rev Anticancer Ther. 2006 Aug;6(8):1165-73. Review.

PMID:
16925483
8.

Therapeutic application of thalidomide in multiple myeloma.

Kyle RA, Rajkumar SV.

Semin Oncol. 2001 Dec;28(6):583-7. Review.

PMID:
11740813
9.

Thalidomide for the treatment of relapsed and refractory multiple myeloma.

Cool RM, Herrington JD.

Pharmacotherapy. 2002 Aug;22(8):1019-28. Review.

PMID:
12173786
10.

Thalidomide and dexamethasone: therapy for multiple myeloma.

Kumar S, Rajkumar SV.

Expert Rev Anticancer Ther. 2005 Oct;5(5):759-66. Review.

PMID:
16221046
11.

Lenalidomide in multiple myeloma.

Thomas SK, Richards TA, Weber DM.

Best Pract Res Clin Haematol. 2007 Dec;20(4):717-35. Review.

PMID:
18070715
12.

Thalidomide in multiple myeloma: past, present and future.

Harousseau JL.

Future Oncol. 2006 Oct;2(5):577-89. Review.

PMID:
17026450
13.

The current status of thalidomide in the management of multiple myeloma.

Glasmacher A, von Lilienfeld-Toal M.

Acta Haematol. 2005;114 Suppl 1:3-7. Review.

PMID:
16166765
14.

Thalidomide: present and future in multiple myeloma.

Hussein MA.

Expert Rev Anticancer Ther. 2005 Feb;5(1):25-31. Review.

PMID:
15757435
15.
16.

Thalidomide in the treatment of multiple myeloma.

Rajkumar SV.

Expert Rev Anticancer Ther. 2001 Jun;1(1):20-8. Review.

PMID:
12113124
17.

Consensus guidelines for the optimal management of adverse events in newly diagnosed, transplant-ineligible patients receiving melphalan and prednisone in combination with thalidomide (MPT) for the treatment of multiple myeloma.

Palumbo A, Davies F, Kropff M, Bladé J, Delforge M, Leal da Costa F, Garcia Sanz R, Schey S, Facon T, Morgan G, Moreau P.

Ann Hematol. 2010 Aug;89(8):803-11. doi: 10.1007/s00277-010-0925-1. Epub 2010 Mar 16.

PMID:
20232066
18.

Intermediate dose thalidomide (200 mg daily) has comparable efficacy and less toxicity than higher doses in relapsed multiple myeloma.

Wechalekar AD, Chen CI, Sutton D, Reece D, Voralia M, Stewart AK.

Leuk Lymphoma. 2003 Jul;44(7):1147-9. Review.

PMID:
12916866
19.

Thalidomide in relapsed/refractory multiple myeloma: pivotal trials conducted outside the United States.

Dimopoulos MA, Anagnostopoulos A.

Semin Hematol. 2003 Oct;40(4 Suppl 4):8-16. Review.

PMID:
15015891
20.

Thalidomide with or without dexamethasone for refractory or relapsing multiple myeloma.

Alexanian R, Weber D, Anagnostopoulos A, Delasalle K, Wang M, Rankin K.

Semin Hematol. 2003 Oct;40(4 Suppl 4):3-7. Review.

PMID:
15015890

Supplemental Content

Support Center